A sector-exclusive life sciences venture and growth equity fund based in Shanghai, China, manages 5 funds with AUM of USD 500M. The firm currently investing from a fund that closed in April 2015, backed by a pharma firm as well as a number of world-class institutional investors. The firm is stage agnostic, investing in early, growth, and up to pre-IPO opportunities. The firm’s team of investment professionals all have a healthcare background. Investment size is USD 5-45 million per company. The firm prefers to lead or co-lead a financing round, and typically requires a board seat. With both USD and RMB funds, the firm on China but also considers opportunities from US, Canada, and Europe.

The firm focuses 75% on therapeutics, with an emphasis on oncology, cell therapy, and biologics. Small molecules are less of interest. The firm is also interested in medical devices, diagnostics, animal health. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large global pharmaceutical company seeks to make strategic investments into early-stage companies that are aligned with the parent firm’s R&D focus. For equity investments, the firm prefers to maintain <15% equity stake in the company, and participate in rounds where lead investors include VC firms or other institutional investors. The venture arm is able to contribute additional non-dilutive resources that can increase the probability of successful product and business development. The group maintains a flexible approach to all investment opportunities. The group seeks to make investments of up to $5M, and usually targets 3-4 investments per year.

The firm’s core focus is on therapeutics, but is also open to invest in improved efficiencies in drug discovery & development, new platforms for target and drug discovery, drug delivery and is beginning to look into digital health solutions that fall within the company’s main R&D focus areas. Currently, the firm is most interested in chronic inflammatory and immune disorders (particularly for gastrointestinal diseases), oncology, regenerative medicine and vaccines; not currently as interested in cardiovascular or CNS indications. The firm does not invest in traditional medical devices or diagnostics. Although the firm is just beginning to explore digital health/health IT, the firm would be open to evaluating healthcare-related software platforms, wearable for health monitoring or digital, companion diagnostics (digital solutions that complement traditional therapeutics).

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm is open to follow-on rounds of investment where they assist in driving promising projects to fruition, and strategic alignment of the investment remains true. The firm respects the autonomy of the institutions it invests in, and will usually seek passive investment terms, providing strategic management input only when requested. However, the firm will require board observer rights and will usually request scientific review rights when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital fund founded in 1992 and based in the US Mid-Atlantic region focuses on healthcare IT and diagnostics. The firm primarily invests in the growth stage at the series A or B round, though if investing early, the firm would be part of a syndicate. The firm typically invests around $1M-$15M into early companies, and $10M-$30M into growth stage companies. The firm seeks to make 10-15 new investments within the next year. The firm focuses on companies based in USA and Canada due to practical matters, though may be open to investments on a global level.

The firm has a primary focus in healthcare IT, particularly in EMR companies, analytics, and any next generation IT tools for enterprise or ambulatory settings. The firm’s secondary focus is in tools and diagnostics, specifically in 510K genomics diagnostics, though is open to any kind of new diagnostic tool or test. The firm currently does not have interest in therapeutics or medical technology. The firm prefers companies with a commercialized product that is producing revenue, though does not have a revenue requirement and may be open to clinical stage products.

The firm primarily invests in growth stage companies where 80% of their invested companies have revenue with a product looking to expand in the market and 20% of invested companies at the pre-revenue, close to commercialization stage. The firm typically invests in pre-revenue companies when the technology is close to commercialization (i.e. steps away from approval) and/or when the company has a strong management team with members the firm has known from before. The firm does not have a management team requirement and will take a board seat depending on the size and ownership of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm based in Europe that provides private equity financing to early- and mid-stage human healthcare and life science companies has raised a new €100 million fund that closed in March 2016. The firm can allocate up to €7M (in equity) per company, always co-investing with other specialized investors and during the whole life of the investment. The firm looks for companies that are based in Europe or the US.

The firm invests in innovative therapeutics, medtech and diagnostics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. For therapeutics, the firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have a solid animal data. For medical devices, the firm is also opportunistic and looks for devices that have a working prototype.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in Australia focuses on late stage therapeutics and medical devices that are past pre-clinical trials. Currently manages a $2.5 billion evergreen fund, and typically invests between $1 and $10 million. The firm normally makes co-investments in the USA, Europe, Israel, and Australia.

The firm is currently looking for new investment opportunities in therapeutics and PMA medical devices. The firm is only interested in later stage technology at Phase II or later, and is particularly interested in peripheral blood-based colorectal cancer diagnostics. The firm is open to all subsectors and indications in therapeutics and medical devices, though is not interested in software-enabled devices or lab equipment and drug development enabling technology. The firm does not invest in pre-clinical products, and only seeks products that are either in clinical trials (Phase II or later) with human data or on-the-market.

The firm seeks companies with an established management team with experience in the field. The firm does not typically take a board seat after an investment. The firm seeks distribution rights for Australia and Southeast Asia from international companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A firm based in Europe has raised a new venture fund of €100 million and is looking to make 4-5 investments over the next 6 to 12 months. The firm could lead any investment up to $15M EUR but will also look for syndicate participation in bigger rounds. Allocations are in the form of equity. Allocations are typically made at the venture stage of development but are open to consider seed through IPO rounds. The firm seeks to invest in any European country and Israel.

The firm will look at a broad spectrum of products and services within the life science space. However, they will not consider drug discovery investments. They will consider anything related to medical devices, diagnostics, in-vitro diagnostics, healthcare IT. They will look at any stage of development within those categories and long as the product or service shows substantial market potential and has proof of concept.

The firm is willing to work with all types of management teams as long as entrepreneurs/founders have a solid knowledge in the industry. A board seat is required for all investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital fund based in Toronto, Canada, looks to make investments in companies ranging from $1 – $5 million initially and up to $10 million over the life of the investment. The firm is looking for companies based within 1000 miles of Toronto. The firm makes approximately 2-3 new investments per year.

Within the life science space the firm is looking for medical device and diagnostics companies that have a clear path to FDA approval. The firm is open to all technology types and indications although they have experience working with assisted living devices and Imaging devices. The firm is looking for companies that have managed to demonstrate market interest in their product prior to investment.

The firm looks to be a very active investor in chosen companies and always pursues a board seat. The firm looks for strong experienced management teams and looks to bring their own entrepreneurial experience to aid in the growth and expansion of companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com